This page is updated frequently with new G Proteins-related patent applications.
| Device for detecting misfolded proteins and methods of use thereof|
The present invention relates to diagnostic devices as well as methods of using these devices for detecting proteins of interest associated with diseases or disorders in mammals. In particular, the proteins of interest may be misfolded proteins associated with certain misfolded-protein disorders in mammals including those mammals suspected of or at risk of having such disorders..
| Protein labeling with cyanobenzothiazole conjugates|
The invention provides compounds and methods for site-specifically labeling proteins with cyanobenzothiazole derivatives of formula i. For example, the invention provides methods for labeling the n-terminus of a protein that terminates with a cysteine residue.
| Novel dna-binding proteins and uses thereof|
Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel dna-binding domains, including tale dna-binding domains. Also disclosed are methods of using these novel dna-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences..
Sangamo Biosciences, Inc.
| Methods and products for expressing proteins in cells|
The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the dna sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic rna molecules.
Factor Bioscience Inc.
| Human antigen binding proteins that bind betta-klotho, fgf receptors and complexes thereof|
The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
| Cd86 antagonist multi-target binding proteins|
This disclosure provides a multi-specific fusion protein composed of a cd86 antagonist binding domain and another binding domain that is an il-10 agonist, an hla-g agonist, an hgf agonist, an il-35 agonist, a pd-1 agonist, a btla agonist, a light antagonist, a gitrl antagonist or a cd40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains.
Aptevo Research And Development Llc
| Binding proteins against vegf, pdgf, and/or their receptors|
Binding proteins that bind one or more of vegf, pdgf and/or their receptors, including antibodies, cdr-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins..
| Long acting proteins and peptides and methods of making and using the same|
Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer ifn-γ conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to ifn-γ, particularly via a free cysteine in the protein.
Bolder Biotechnology, Inc.
|Oncostatin m receptor antigen binding proteins|
The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. Osmr antigen binding proteins interfere with binding of osm and/or il-31 to osmr.
Kiniksa Pharmaceuticals, Ltd.
|Fusion proteins comprising igg2 hinge domains|
The present invention relates to biologically active fusion proteins containing the igg2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins.. .
Uses of diazepane derivatives
The present invention provides compounds of formula (ii) (e.g., compounds of formula (i)), and pharmaceutically compositions thereof. Compounds of formula (ii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
Methods and compositions for the stabilization of proteins
The present disclosure relates to buffer-stabilized protein compositions and methods of making the same. The disclosed compositions and methods provide a means of stabilizing and preserving proteins or peptides in such a way that the proteins or peptides maintain their native conformation and structure, maintain biological activity, and prevent aggregation..
Method to identify compounds able to bind to the rossmann fold of c-terminal-binding proteins, identified compounds and medical uses thereof
The invention refers to a method for identifying an anti-tumoral and/or anti-proliferative and/or an inhibitor of the fission machinery involved in mitotic golgi partitioning and/or a molecule modulator of ctbp corepressor activity by testing their affinity binding for the rossmann fold of c-terminal-binding proteins (ctbps); to said identified molecules and to the use thereof as anti-proliferative and/or anti tumoral agents.. .
Consiglio Nazionale Delle Ricerche
Multi-specific binding proteins
This invention generally relates to multi-specific binding proteins. The invention also relates to methods of making such proteins and to methods of using such proteins.
Boehringer Ingelheim International Gmbh
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.. .
St2 antigen binding proteins
Described herein are compositions and methods related to antigen binding proteins that bind to human st2, including antibodies. In particular embodiments, the disclosure provides fully human anti-st2 antibodies and deriviatives and variants thereof.
Human il-23 antigen binding proteins
Antigen binding proteins that bind to human il-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of il-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided..
Avian colony stimulating factor 1 receptor binding proteins
The present invention provides avian csf1 genes encoding proteins which bind avian colony stimulating factor 1 receptor (csf1r) and which exhibit immunomodulatory properties.. .
The University Court Of The University Of Edinburgh
Cephalopod proteins as proton conductors
The disclosed invention relates to novel materials and associated methods for conducting protons, such materials comprising cephalopod proton-conducting proteins such as reflectins. The protonic conductivity of such cephalopod proton-conducting proteins may be modulated by the application of an electric field.
The Regents Of The University Of California
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
The present invention provides a method of treating bph using modified pore-forming proteins (mpps). These mpps are derived from naturally occurring cytotoxic proteins (npps) that kill cells by forming pores or channels in the cell membrane, resulting in cell death.
Sophiris Bio Inc.
Nanopore biosensors for detection of proteins and nucleic acids
Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties..
Katholieke Universiteit Leuven
Co-expression of magnetotactic bacterial genes and genes encoding iron handling proteins in cells
The invention provides an improved modified magnetosome that contains more iron therein with the combination of the expressed genes. This is achieved by co-expression of (a) one or more bacterial magnetotactic genes to amplify iron uptake, compartmentalization and biomineralization in cells, with (b) one or more mammalian iron handling proteins that together augment(s) and/or regulate the cells iron pool.
Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb)
A method of non-thermally ablating undesirable tissue in the body by application of pulsed, bipolar, instant charge reversal electrical fields of sufficient energy to cause complete and immediate cell membrane rupture and destruction. Energy is delivered through radio frequency pulses of particular frequencies, wave characteristics, pulse widths and pulse numbers, such that enhanced physical stresses are placed on the cell membrane to cause its immediate and complete destruction thereby spilling the entire cell content and membrane constituents into, the extracellular space without denaturing proteins so as to enable an immunological response to destroy and remove the target tissue and similarly marked tissue elsewhere in the subject..
Rfemb Holdings, Llc
Icos binding proteins
The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited
Protein sustained-release injectable formulation
The present invention provides sustained-release pharmaceutical formulations for administering proteins to the eye. In particular, the invention provides formulations comprising single chain antibodies and hydrophobic polyester hexylsubstituted poly(lactic acid) (hexpla).
Esbatech - A Novartis Company Llc
Recombinant binding proteins and their use
New designed ankyrin repeat domains with binding specificity for serum albumin, recombinant binding proteins comprising at least two designed ankyrin repeat domains with binding specificity for serum albumin, as well as recombinant binding proteins comprising at least one designed ankyrin repeat domain with binding specificity for hepatocyte growth factor (hgf), at least one designed ankyrin repeat domain with binding specificity for vascular endothelial growth factor (vegf-a), and at least two designed ankyrin repeat domain with binding specificity for serum albumin are described, as well as nucleic acids encoding such designed ankyrin repeat domains and recombinant binding proteins, pharmaceutical compositions comprising such designed ankyrin repeat domains, recombinant binding proteins or nucleic acids and the use of such designed ankyrin repeat domains, recombinant binding proteins, nucleic acids or pharmaceutical compositions in the treatment of diseases.. .
Molecular Partners Ag
Compounds targeting proteins, compositions, methods, and uses thereof
The present invention provides modulators of protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses.
Methods and systems for extracting protein and carbohydrate rich products from a microcrop and compositions thereof
The present disclosure relates, according to some embodiments, to methods and systems for purifying proteins and carbohydrate rich products from photosynthetic aquatic species and compositions thereof. For example, one embodiment of the present disclosure relates to methods and systems for purifying proteins the present disclosure relates, in some embodiments to methods and systems for extracting proteins, dry biocrude, and carbohydrate-rich meal from lemna.
Apparatuses, methods, and systems for cultivating a microcrop involving a floating coupling device
The present disclosure relates, according to some embodiments, to apparatuses, methods, and systems for cultivating a microcrop involving a floating coupling device. More specifically, the present disclosure relates, in some embodiments to apparatuses and methods for cultivating lemna for extracting proteins and/or carbohydrate rich products.
Methods and systems for organic solute sampling of aqueous and heterogeneous environments
Provided are computer implemented methods for organic solute sampling in aqueous and heterogeneous environments using oscillating chemical potentials in grand canonical monte carlo simulations. The methods involve gcmc of both the solutes and water, with the excess chemical potential (μex) of both the solute and the water oscillated to attain their target concentrations in the simulation system.
University Of Maryland, Baltimore
Cell penetrating protein adaptor molecules and their application in research and medicine
Coupling proteins that make strong protein-protein interactions equipped with cell penetrating peptides (cpps) provide a convenient and powerful method to perturb cell interiors; there are many potential payloads and a broad palette of selectively membrane permeable probes. In a preferred embodiment, the coupling protein will be calmodulin or a related calcium binding protein.
Kennesaw State University Research And Service Foundation Inc.
Dimeric iap inhibitors
Molecular mimics of smac are capable of modulating apoptosis through their interaction with cellular iaps (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the n-terminal tetrapeptide of iap-binding proteins, such as smac/diablo, hid, grim and reaper, which interact with a specific surface groove of iap.
Tetralogic Birinapant Uk Ltd.
Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages
The present invention relates to a system and method for controlling peptide display valency on virus-like particles (vlps), especially including ms2 vlps. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single rna.
Methods for diagnosing diseases associated with human signal peptide-containing molecules
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Antibodies comprising chimeric constant domains
Antibodies, antigen-binding proteins and fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric fc-containing antibodies, antigen-binding proteins and fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric fc-containing proteins are provided..
Regeneron Pharmaceuticals, Inc.
Process for producing and purifying factor viii and its derivatives
Disclosed is a method for producing proteins having factor viii procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate.
Sk Chemicals Co., Ltd.
Dihydropteridinone derivatives and uses thereof
The present invention provides compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
Diazepane derivatives and uses thereof
The present invention provides compounds of any one of formulae (i), (ii-c) (e.g., formula (ii)), and (iii), and pharmaceutically compositions thereof. Compounds of any one of formulae (i), (ii-c), and (iii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
Compositions and methods for quantitative assessment of dna-protein complex density
One aspect of the present invention describes materials and methods of quantitatively measuring the density or percent occupancy of dna binding proteins such as histones, histone variants, histone post translational modifications and transcription factors in chromatin at given dna loci. One embodiment measures a factor's average quantity at specific gene loci, and controls for a number of pitfalls concerning antibody quality and handling issues.
The University Of Chicago
Rapid protein labeling and analysis
The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein.
Life Technologies Corporation
Trispecific binding proteins and methods of use
Provided herein are trispecific antigen-binding proteins comprising a domain binding to cd3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins.
Harpoon Therapeutics, Inc.
Anti-mesothelin binding proteins
The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment..
Human c-fms antigen binding proteins
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided.
The invention provides antibodies that specifically bind to pd-l1 and fusion molecules comprising pd-l1 binding proteins constructed with an il15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit pd-l1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases..
Kadmon Corporation, Llc
Coronavirus proteins and antigens
Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (pedv) or porcine delta coronavirus (pdcov).
Mj Biologics, Inc.
Methods and kits for isolation and analysis of a chromatin region
The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.. .
Board Of Trustees Of The University Of Arkansas
Methods and products for transfecting cells
The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using rna are disclosed.
Factor Bioscience Inc.
Tethering cysteine residues using cyclic disulfides
Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including sod1 and dj-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker.
Chimeric antigen receptor compositions
Provided herein are compositions which exhibit novel diagnostic capabilities and allow to rapidly add functionality to adoptive immunotherapy. The compositions include isolated nucleic acids encoding proteins including antibody regions capable of binding compounds including a peptidyl moiety (e.g., a meditope).
City Of Hope
Antibodies against tl1a and uses thereof
The disclosure provides tnf-like ligand 1a (tl1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to tl1a and inhibits interaction of tl1a and death receptor 3 (dr3) and which does not inhibit the interaction of tl1a and decoy receptor 3 (dcr3). The disclosure also provides uses of the tl1a-binding proteins..
Teva Pharmaceuticals Australia Pty Ltd
Antigen binding proteins
The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid p component (sap), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, alzheimer's disease, and type 2 diabetes..
Glaxo Group Limited